重新定义手术在寡转移IV期黑色素瘤治疗中的作用
本文讨论了在有效系统治疗(尤其是免疫治疗)时代,寡转移IV期黑色素瘤患者中手术角色的转变。目前治疗选择包括先手术后辅助免疫治疗或先免疫治疗必要时挽救手术。决策需在专科多学科团队中进行并个体化,尚需高级别临床试验证据。
要点
- 无症状孤立或寡转移患者可选先手术后辅助免疫或先免疫治疗必要时挽救手术。
- 疑似孤立或寡转移的手术兼具诊断和治疗目的。
- 决策需在黑色素瘤多学科团队中个体化制定,手术不可行时立体定向放疗可替代。
核心结论
- 有效系统治疗时代,寡转移IV期黑色素瘤的手术角色已改变,需在多学科团队中个体化决策。
研究设计与样本
- 本文为综述,未报告系统检索范围与样本量。
主要发现
- 无症状孤立或寡转移患者可选先手术后辅助免疫治疗或先免疫治疗必要时挽救手术。
- 手术对疑似孤立或寡转移兼具诊断和治疗目的。
- 手术并发症通常比严重免疫相关不良事件更可耐受,但手术可能效果较差。
- 先免疫治疗可避免快速进展疾病接受无效手术,并提供评估治疗反应的机会。
- 若免疫治疗中疾病进展至不可切除,可能错过手术窗口;局部治疗推荐但不愿手术时立体定向放射外科可替代。
临床怎么用
- 疑似孤立或寡转移可考虑手术诊断兼治疗。
- 无症状孤立或寡转移可选择先手术后辅助免疫或先免疫治疗必要时挽救手术。
- 决策应在专科黑色素瘤多学科团队中进行并个体化。
- 局部治疗推荐但不愿手术时,可考虑立体定向放射外科。
局限性
- 需高级别临床试验证据解决不确定性,但表现复杂可能使试验设计困难。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Although previously the mainstay of treatment, the role of surgery in the management of patients with oligometastatic stage IV melanoma has changed with the advent of effective systemic therapies (most notably immunotherapy). Contemporary treatment options for patients with asymptomatic solitary or oligo-metastases include upfront surgery followed by adjuvant immunotherapy or upfront immunotherapy with salvage surgery as required. For suspected solitary or oligo-metastases, surgery serves both diagnostic and therapeutic purposes. Advances in radiological technology allow metastases to be detected earlier and surgery to be less morbid. Surgical morbidities are generally more tolerable than serious immune-related adverse effects, but surgery may be less effective. Upfront immunotherapy ensures that futile surgery is not offered for rapidly progressive disease. It also provides an opportunity to assess response to treatment, which predicts outcome, and may obviate the need for surgery. However, it is important not to miss a window of opportunity for surgical intervention, whereby if disease progresses on immunotherapy it becomes unresectable. In situations where local therapy is recommended but surgery is not desired, stereotactic radiosurgery may be an effective alternative. The decision-making process regarding upfront surgery versus immunotherapy needs to take place within a specialist melanoma multidisciplinary setting and be customised to individual patient and tumour factors. Ultimately, high-level clinical trial evidence is required to resolve uncertainties in the management of patients with oligometastatic stage IV melanoma but the complexity of the varying presentations may make trial design challenging.
引用
- Ch'ng S, Uyulmaz S, Carlino MS, et al. Re-defining the role of surgery in the management of patients with oligometastatic stage IV melanoma in the era of effective systemic therapies. Eur J Cancer. 2021. PMID: 34126335. doi:10.1016/j.ejca.2021.04.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。